These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21501034)

  • 1. Ritonavir-boosted protease inhibitors in HIV therapy.
    Hull MW; Montaner JS
    Ann Med; 2011 Aug; 43(5):375-88. PubMed ID: 21501034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic enhancers for HIV drugs.
    Xu L; Desai MC
    Curr Opin Investig Drugs; 2009 Aug; 10(8):775-86. PubMed ID: 19649922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
    Zeldin RK; Petruschke RA
    J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature.
    Bernecker C; West TB; Mansmann G; Scherbaum WA; Willenberg HS
    Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):125-7. PubMed ID: 22328106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients.
    Scott JD
    Am J Health Syst Pharm; 2005 Apr; 62(8):809-15. PubMed ID: 15821273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
    Shah BM; Schafer JJ; Priano J; Squires KE
    Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
    Sension M; Piliero PJ
    J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
    Shuter J; Sarlo JA; Rode RA; Zingman BS
    HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoenhancement of protease inhibitors.
    Motwani B; Khayr W
    Am J Ther; 2006; 13(1):57-63. PubMed ID: 16428923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.